BridgeBio Pharma Inc (BBIO)
24.85
+0.52
(+2.14%)
USD |
NASDAQ |
Apr 26, 16:00
24.85
0.00 (0.00%)
After-Hours: 18:34
BridgeBio Pharma Free Cash Flow (Quarterly): -125.25M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -125.25M |
| September 30, 2023 | -145.66M |
| June 30, 2023 | -113.78M |
| March 31, 2023 | -144.33M |
| December 31, 2022 | -94.04M |
| September 30, 2022 | -135.92M |
| June 30, 2022 | -34.36M |
| March 31, 2022 | -161.49M |
| December 31, 2021 | -136.43M |
| September 30, 2021 | -163.02M |
| June 30, 2021 | -94.00M |
| March 31, 2021 | -152.73M |
| Date | Value |
|---|---|
| December 31, 2020 | -98.41M |
| September 30, 2020 | -132.23M |
| June 30, 2020 | -88.20M |
| March 31, 2020 | -88.40M |
| December 31, 2019 | -75.45M |
| September 30, 2019 | -50.38M |
| June 30, 2019 | -68.83M |
| March 31, 2019 | -61.57M |
| December 31, 2018 | -47.16M |
| September 30, 2018 | -38.93M |
| June 30, 2018 | -35.61M |
| March 31, 2018 | -33.13M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-163.02M
Minimum
Sep 2021
-34.36M
Maximum
Jun 2022
-110.68M
Average
-113.78M
Median
Jun 2023
Free Cash Flow (Quarterly) Benchmarks
| Pfizer Inc | 4.196B |
| Alnylam Pharmaceuticals Inc | -45.10M |
| Ardelyx Inc | -8.761M |
| Regenxbio Inc | -41.89M |
| IDEAYA Biosciences Inc | -24.59M |